Trial · NCT07888257
Registered outcomes33
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 33
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | βHB response to exogenous βHB supplementation | 3-16 weeks | βHB area under the curve (AUC) from fasting and repeated postprandial blood samples after drink intake, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Time course of βHB concentrations | 3-16 weeks | Fasting concentrations and time course of βHB concentrations at individual time points including derived metrics (e.g., peak concentration, time to peak, rate of change), compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Fasting and postprandial glucose and insulin response | 3-16 weeks | Fasting concentrations and postprandial time course of glucose, insulin and C-peptide in repeated blood samples after drink intake, including derived metrics (e.g., incremental area under the curve \[iAUC\], incremental peak, time to peak, amplitude, nadir, rate of change) and indices of insulin sensitivity (e.g., HOMA-IR), compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Concentration of inflammatory markers | 3-16 weeks | Interleukin-6 (IL-6) and hsCRP levels measured in fasting blood samples; IL-6 additionally in postprandial blood samples after drink intake, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Metabolic and stress-responsive hormones | 3-16 weeks | Growth differentiation factor 15 (GDF15), fibroblast growth factor 21 (FGF21) and cortisol concentrations in fasting and postprandial blood samples, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Gut and appetite-regulating hormones | 3-16 weeks | Glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), ghrelin and leptin concentrations in fasting and postprandial blood samples, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Lipolysis and energy metabolites | 3-16 weeks | Free fatty acids, triglycerides, lactate and amino acids in fasting and postprandial blood samples, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Oxidative stress markers | 3-16 weeks | Oxidative stress markers such as Malondialdehyde and 3-Nitrotyrosine in fasting and postprandial blood samples, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Avoidance behavior | 3-16 weeks | Time spent in less safe areas and exploratory movement in two virtual reality scenarios (elevated platform, dark maze), compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Risky decision-making | 3-16 weeks | Choice behavior in a lottery task during fMRI (e.g., proportion of risky choices, risk attitude), compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Dual-task performance | 3-16 weeks | Reaction times, accuracy and dual-task costs in an auditory-visual dual-task paradigm, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Heart rate and heart rate variability (HRV) | 3-16 weeks | Heart rate and heart rate variability (HRV) from electrocardiography, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Skin conductance response | 3-16 weeks | Electrodermal activity (EDA) measured via electrodermal activity electrodes, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Respiration rate | 3-16 weeks | Task-based and resting-state respiration rate, measured via a respiration belt pulse (pulse oximetry during MRI), compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Pulse | 3-16 weeks | Pulse measured via pulse oximetry during MRI, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Gastric myoelectric activity | 3-16 weeks | Gastric rhythm and power assessed by electrogastrography (EGG), compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Brain Structure | 3-16 weeks | Brain morphology (e.g., regional gray matter volume and density) assessed by T1-weighted structural MRI, compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | White matter micro- and macrostructure | 3-16 weeks | White matter micro- and macrostructure assessed by diffusion-weighted imaging (DWI), compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Resting-state functional connectivity | 3-16 weeks | Functional connectivity between brain regions assessed by resting-state functional MRI (rs-fMRI), compared between drink conditions (βHB vs. placebo) and glycemic groups |
| Primary | Task-related brain activity | 3-16 weeks | Brain activity during a risk-based decision-making task (lottery task) assessed by functional MRI (fMRI), compared between drink conditions (βHB vs. placebo) and glycemic groups |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07888257/registered